UnknownPHASE1, PHASE2NCT02569463
Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS）
Studying Macrophage activation syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peking University People's Hospital
- Principal Investigator
- Zhanguo LiDepartment of Rheumatology and Immunology,Peking University People's Hospital
- Intervention
- Interleukin-2(drug)
- Enrollment
- 6 enrolled
- Eligibility
- 16-65 years · All sexes
- Timeline
- 2014 – 2018
Study locations (1)
- Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02569463 on ClinicalTrials.gov